Evidence map›Paper›PMID 40872882›Full record

ArticleVaccines2025

Evaluation of Poxvirus-Specific Antibody Response in Monkey Poxvirus-Negative and -Positive Cohorts.

Nannan Jia, Lin Ai, Yunping Ma, Chen Hua, Qi Shen, Chen Wang, Teng Li, Yingdan Wang, Yunyi Li, Yin Yang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nannan JiaShanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Lin AiInstitute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201100, China.
Yunping MaKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Chen HuaKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.ORCID 0000-0002-3066-7434
Qi ShenInstitute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201100, China.
Chen WangShanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Teng LiShanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Yingdan WangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Yunyi LiInstitute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201100, China.
Yin YangShanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Chi ZhouShanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Min ChenInstitute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201100, China.
Huanyu WuInstitute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201100, China.
Xin ChenInstitute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201100, China.
Lu LuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.ORCID 0000-0002-2255-0391
Yanqiu ZhouInstitute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201100, China.
Jinghe HuangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Fan WuShanghai Immune Therapy Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.

Funding

Genetic Evolution Characteristics and Key Techniques for Tracing of Highly Pathogenic Viruses NO. 2023YFC2605602 to X.C.Key Discipline- Infectious Diseases of Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System (2023-2025) No. GWVI-11.1-01 to J.C.National Key Research and Development Program of China 2023YFE0118200 to F.W.National Natural Science Foundation of China 32370995 and 31771008 to J.H.Shanghai Municipal Science and Technology Major Project ZD2021CY001 to J.H.Shanghai Municipal Science and Technology Major Project ZD2021CY001 to M.C."Shuguang Program" of Shanghai Education Development Foundation and Shanghai Municipal Education Commission 22SG16 to F.W.the Key Discipline Program on Public Health System Construction of Shanghai GWVI-11.1-15 to M.C.the key research project of Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2023-2025) GWVI-3 to M.C.Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2023-2025) Key Discipline Project No. GWVI-11.1-12 to S.L.
6 · The paper itself

Abstract

objectivesUnderstanding the antibody response in monkeypox virus (MPXV)-infected and uninfected individuals is essential for developing next-generation MPXV vaccines. This study aimed to characterize neutralizing antibody (NAb) and antibody-dependent cellular cytotoxicity (ADCC) responses in both groups, providing insights into immune protection and vaccine design.

methodsA recombinant vaccinia Tian Tan (VTT) virus was utilized to develop high-throughput luciferase-reporter-based neutralization and ADCC assays. These assays were applied to evaluate the presence and levels of poxvirus-specific antibodies in MPXV-infected and uninfected individuals, including those vaccinated with vaccinia-based vaccines.

resultsPoxvirus-specific NAbs were detected in MPXV-negative individuals with prior vaccinia vaccination. However, MSM individuals exhibited significantly lower pre-existing NAb levels than non-MSM individuals, potentially contributing to their higher susceptibility to MPXV infection. In individuals with mild MPXV infection, robust NAb and ADCC responses were observed, regardless of vaccination status. Additionally, HIV-positive individuals demonstrated comparable antibody responses following MPXV infection.

conclusionsThese findings highlight the potential role of pre-existing NAbs in MPXV susceptibility and the strong immune response elicited by mild MPXV infection. Further research is needed to determine whether MPXV-specific antibodies mitigate disease progression, which could inform the development of effective MPXV vaccines.

Indexed as

ADCCmonkey poxvirusMSMneutralizing antibodies

Identifiers

PMID40872882
PMCPMC12389981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.